We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Constellation Brands
STZ
$22.6B
| $461K | ﹤0.01% |
2,834
-1,286
| -31% | -$231K |
|
1352
Assembly Biosciences
ASMB
$687M
| $460K | ﹤0.01% |
25,394
| – | – |
|
1353
Landstar System
LSTR
$6.14B
| $458K | ﹤0.01% |
3,295
-960
| -23% | -$133K |
|
1354
Scorpio Tankers
STNG
$3.92B
| $451K | ﹤0.01% |
11,530
+2,287
| +25% | +$89.2K |
|
1355
Ormat Technologies
ORA
$6.36B
| $451K | ﹤0.01% |
5,380
-62
| -1% | -$4.63K |
|
1356
Thor Industries
THO
$4B
| $449K | ﹤0.01% |
5,061
-1,973
| -28% | -$156K |
|
1357
Valvoline
VVV
$4.09B
| $449K | ﹤0.01% |
11,866
-169
| -1% | -$5.91K |
|
1358
Ubiquiti
UI
$36.6B
| $449K | ﹤0.01% |
1,091
-211
| -16% | -$76.8K |
|
|
NXRT
1359
NexPoint Residential Trust
NXRT
$608M
| $445K | ﹤0.01% |
13,355
+845
| +7% | +$29.9K |
|
1360
MGM Resorts International
MGM
$10.8B
| $444K | ﹤0.01% |
12,918
-1,243
| -9% | -$39.4K |
|
1361
Amphenol
APH
$197B
| $443K | ﹤0.01% |
4,488
-74,173
| -94% | -$6.07M |
|
1362
Ennis
EBF
$547M
| $442K | ﹤0.01% |
24,388
-419
| -2% | -$7.85K |
|
1363
Asana
ASAN
$2.36B
| $442K | ﹤0.01% |
32,748
+17
| +0.1% | +$266 |
|
1364
New Jersey Resources
NJR
$5.47B
| $438K | ﹤0.01% |
9,764
-329
| -3% | -$15.4K |
|
1365
NOV
NOV
$7.33B
| $436K | ﹤0.01% |
35,076
-984
| -3% | -$12.4K |
|
1366
Novanta
NOVT
$5.47B
| $433K | ﹤0.01% |
3,358
-43
| -1% | -$5.23K |
|
1367
Quaker Houghton
KWR
$2.9B
| $433K | ﹤0.01% |
+3,865
| New | +$420K |
|
1368
Gentherm
THRM
$1.23B
| $431K | ﹤0.01% |
+15,244
| New | +$405K |
|
1369
Timken Company
TKR
$8.53B
| $431K | ﹤0.01% |
5,943
-99
| -2% | -$6.73K |
|
1370
Graham Holdings Company
GHC
$4.92B
| $431K | ﹤0.01% |
455
+136
| +43% | +$128K |
|
1371
Ingevity
NGVT
$2.4B
| $429K | ﹤0.01% |
9,952
-11,187
| -53% | -$432K |
|
1372
Bruker
BRKR
$8.77B
| $425K | ﹤0.01% |
10,326
-153
| -1% | -$5.91K |
|
1373
Sabra Healthcare REIT
SBRA
$5.3B
| $425K | ﹤0.01% |
23,070
-643
| -3% | -$11.4K |
|
1374
Hexcel
HXL
$7.1B
| $424K | ﹤0.01% |
7,507
-175
| -2% | -$9.25K |
|
1375
Essex Property Trust
ESS
$18.1B
| $423K | ﹤0.01% |
1,494
-368
| -20% | -$103K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.